(RxWiki News) The makers of Zerenex have announced positive results from a three-phase study addressing the efficacy of the drug intended for dialysis patients with end-stage renal disease (ESRD).
Keryx Biopharmaceuticals has developed Zenerex as a treatment for elevated serum phosphorus levels, and so far the drug appears to be safe and well-tolerated. The drug demonstrated a statistically significant dose response in the study.
Keryx CEO called the development "perhaps the most important milestone in Keryx's history," as the company moves into a long-term study of the drug.
End-stage renal disease is the fifth and final stage of chronic kidney disease (CKD), the progressive loss in kidney function over a period of months or years. Symptoms of CKD include: decreased urine output or no urine output, nausea, vomiting, loss of appetite, muscle twitches and cramps, swelling in the feet and ankles, decreased mental sharpness, persistent itchiness and sleep problems, among others.
